Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCL

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCLПодробнее

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZLПодробнее

Obinutuzumab plus venetoclax in early R/R DLBCLПодробнее

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCLПодробнее

Overview of a Phase Ib study of venetoclax and obinutuzumab in CLLПодробнее

Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphomaПодробнее

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?Подробнее

Atezolizumab with venetoclax and obinutuzumab in patients with CLLПодробнее

Atezolizumab, Obinutuzumab, and Venetoclax provide durable remissions for untreated DLBCL-RS ptsПодробнее

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLLПодробнее

Venetoclax and obinutuzumab for CLLПодробнее

Ideal patient for Venetoclax/Obinutuzumab combination | Dr. Jeff Sharman | Oncology Brothers #2023Подробнее

Obinutuzumab + Venetoclax for Frontline CLLПодробнее

Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLLПодробнее

CLL14: Venetoclax plus obinutuzumab for CLLПодробнее

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLLПодробнее

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLLПодробнее

Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLLПодробнее

Venetoclax and Obinutuzumab in CLLПодробнее